Combined androgen blockade.
Combined therapy, the treatment of advanced adenocarcinoma of the prostate by total androgen suppression, is still a controversial subject today. Some studies performed during the 1980s support the value of this therapeutic approach, while others have found it to be no more effective than surgical or chemical castration alone. Recently, the results of a randomized, controlled, multicenter intergroup study of combined therapy sponsored by the U.S. National Cancer Institute (NCI) became available. These results suggest that combined therapy offers some advantages over monotherapy in the treatment of advanced prostate cancer. A variety of drugs are available to suppress adrenal androgens. However, the value of these agents in prostate cancer therapy continues to be hotly debated.
Crawford
E D
ED
Division of Urology, University of Colorado School of Medicine, Denver.
D000230:Adenocarcinoma / Q000628:therapy*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone; D004054:Diethylstilbestrol; D016729:Leuprolide